Search results
Added:
8 months ago
EASD 24 - We are joined by Dr Richard Pratley (AdventHealth Diabetes Institute, US) to discuss the kidney, cardiovascular, metabolic, mortality and safety results from the FLOW trial.Interview Questions:1. What is the reasoning behind the FLOW Trial?2. What was the patient population and study design?3. What are the key results?4. Were there any surprising or unexpected findings?5. What further…
View more
Added:
1 month ago
EHRA 2025 - Positive safety results of the Affera mapping and ablation system for the treatment of ventricular arrhythmias (VA) show a 6% rate of major complication.Dr Frédéric Sacher (IHU Liryc, Bordeaux, FR) joins us on-site at EHRA Congress 2025 to discuss safety results from the European Affera Ventricular Arrhythmia Ablation Registry, investigating VA ablation with the Affera Sphere-9…
View more
Added:
5 months ago
AHA Conference 2024 - BROOKLYN: Safety and efficacy outcomes of obicetrapib (NewAmsterdam Pharma) alongside lipid-lowering therapy in Heterozygous Familial Hypercholesterolemia (HeFH) management.Dr Stephen Nicholls (Monash University and The Victorian Heart Hospital, Melbourne, AU) joins us onsite at AHA Conference to discuss the findings from BROOKLYN (NCT05425745).BROOKLYN is a phase 3,…
View more
Added:
1 year ago
A single centre, prospective, non-randomised study from DrDaniela Trabattoni (Monzino Cardiology Centre,Milan, IT) following device implantation of the Occlutech PFO Closure device in 442 consecutive patients.The study is particularly interesting due to the scarcity of data available on the long term follow up (over 5 years after) of device implantation. Also, the results are focussed not only…
View more
Added:
9 months ago
Added:
6 months ago
AHA Conference 2024 — REALIZE-K: Impact of sodium zirconium cyclosilicate (SZC) on HFrEF patient's potassium levels whilst on spironolactone.Late-Breaker Host, Dr Harriette Van Spall (McMaster University, CA) is joined onsite by Dr Mikhail Kosiborod (Saint Luke's Mid America Heart Institute, US) to discuss the findings from the REALIZE-K Study (NCT04676646; AstraZeneca).REALIZE-K is a phase 4…
View more
Added:
3 days ago
ESC HF 25 - A study investigating CRISPR gene editing with nexiguran ziclumeran in ATTR cardiomyopathy demonstrated favourable safety and tolerability, with consistent reductions in serum TTR in both wild-type and variant disease.Prof Marianna Fontana (University College London, UK) joins us to discuss the key findings from a two-part, open-label, phase 1 study investigating the treatment effect,…
View more
Added:
3 days ago
ESC HF 25 - Safety outcomes from PRAISE-HFrEF show that glucagon-like peptide-1 receptor agonism (GLP-1 RA) treatment for heart failure with reduced ejection fraction (HFrEF) and obesity was not associated with increased risk of heart failure hospitalisation or mortality compared to placebo, with greater benefits observed in patients with higher BMI.Dr Varun Sundaram (Case Western Reserve…
View more
Added:
1 day ago
ESC HF 25 - In a FINEARTS HF post-hoc analysis, the relative and absolute effects of finerenone relative to placebo did not significantly differ across kidney function.We are joined by Dr Safia Chatur (Mass General Cardiology, US) to discuss key findings from the FINEARTS-HF trial. This Phase 3 study evaluated the effect of finerenone versus placebo on cardiovascular death and total heart failure…
View more
Added:
3 weeks ago
Safety and effectiveness outcomes of a 3-in-1 carotid stent delivery system show no major strokes at 30-day and one-year follow ups and significantly low rates of clinically driven target lesion revascularisation at two years.Dr William Gray (Main Line Health, Pennsylvania, US) joins us to discuss the first European presentation of the two-year outcomes from PERFORMANCE II (NCT04201132; Contego…
View more
